Clinical Data
Reddy D., Peter M., Shah T.T., et al. | European Urology | February 2022
Study Size: N = 1379 | Median Age: 66 | Pre-HIFU Median PSA: 6.9
Follow Up: ≥6 Mo. | Median Follow Up: 32 Mo.
This study as published in European Urology reported on oncologic outcomes and adverse events following focal Sonablate high intensity focused ultrasound for treating nonmetastatic prostate cancer. The data was prospectively recorded in the HIFU Evaluation and Assessment of Treatment (HEAT) registry and included 1379 men with at least 6 months of follow up data. It is important to note that this study includes data from 13 UK centers and that 24% of the patients had at least five years of follow up, with some follow up going out as far as 15 years. This data shows the durability of outcomes for focal Sonablate HIFU and that successful programs can be implemented with multiple users.
"Focal Sonablate HIFU in carefully selected patients with clinically significant prostate cancer, with six and three of ten patients having respectively, intermediate-and high-risk cancer, has good cancer control in the medium term."
Shah T.T., Reddy, D., Peters, M., et al. | Prostate Cancer and Prostatic Diseases| January 2021
N = 492 patients
246 Radical Prostatectomy|246 Focal Therapy patients (Sonablate HIFU and Cryotherapy)
Recently published in the Prostate Cancer and Prostatic Diseases, the authors of this study used prospective multi-center databases of 761 Focal therapy cases (626 Sonablate HIFU / 135 Cryotherapy) and 572 radical prostatectomy cases between November 2005 – 2018. After matching, 246 focal therapy patients and 246 radical prostatectomy were identified. The primary outcome was to determine differences in failure-free survival (FFS) between the focal therapy and radical prostatectomy cohorts.
In patients with non-metastatic low- intermediate prostate cancer, oncological outcomes over 8 years were similar between focal therapy and radical prostatectomy."
Following Focal Therapy for Prostate Cancer: A
Prospective Multicenter Evaluation
Ghoreifi, A., Kaneko, M., Peretsman, S., et al. | European Urology Open Science| February 2023
N = 143 patient respondents|3 validated questionnaires during a post operative period of 26-68 months
There are several reports regarding decision satisfaction/regret for patients receiving conventional treatments (radical and active surveillance), however there was limited data about patients undergoing focal therapy. The authors’ main objective of this study was to evaluate the treatment decision satisfaction and regret among patients who underwent focal therapy for prostate cancer with high-intensity focused ultrasound (HIFU) or cryoablation (CRYO).
"Focal Therapy using HIFU and CRYO for localized prostate cancer is well accepted by the patients, with a low regret rate."
Up to 25% of patients may experience regret following their conventional treatment; the most common factors associated with regret were treatment toxicity, urinary and particularly sexual, dysfunction.
Ready for the most customizable focal therapy option?
Are you delaying building your focal therapy program due to potential challenges or complications?
We have created a webinar series to provide guidance from physicians just like you who have built successful programs.
